Hot Features
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinica... COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.215 | 1.80900294489 | 11.885 | 14.76 | 11.8 | 5120701 | 13.46394025 | DR |
| 4 | 2.7 | 28.7234042553 | 9.4 | 14.76 | 9.22 | 4427177 | 11.68722545 | DR |
| 12 | 5.4 | 80.5970149254 | 6.7 | 14.76 | 4.88 | 4131492 | 9.36148819 | DR |
| 26 | 6.41 | 112.653778559 | 5.69 | 14.76 | 4.88 | 3290260 | 8.51083712 | DR |
| 52 | 7.5 | 163.043478261 | 4.6 | 14.76 | 2.25 | 2810708 | 6.79618148 | DR |
| 156 | 4.24 | 53.9440203562 | 7.86 | 14.76 | 2.25 | 1394543 | 6.6119332 | DR |
| 260 | -21.13 | -63.5871200722 | 33.23 | 49.515 | 2.25 | 987674 | 8.8297948 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.